64614-49-9

Basic information

• Product Name: 4-[(6-chloropyridin-3-yl)carbonyl]morpholine
• Synonyms: 4-[(6-chloropyridin-3-yl)carbonyl]morpholine;(6-chloro-pyridin-3-yl)-morpholin-4-yl-methanone;Albb-004234;4-[(6-chloro-3-pyridinyl)carbonyl]morpholine(SALTDATA: FREE);4-[(6-chloro-3-pyridinyl)carbonyl]morpholine;(6-chloropyridin-3-yl)(Morpholino)Methanone;(6-Chloropyridin-3-yl);(morpholino)
• CAS NO: 64614-49-9
• Molecular Formula: C₁₀H₁₁ClN₂O₂
• Molecular Weight: 226.66
• Product Categories: alkyl chloride
• Mol File: 64614-49-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 410.6°C at 760 mmHg
• Flash Point: 202.1°C
• Appearance: /
• Density: 1.327g/cm³
• Vapor Pressure: 5.93E-07mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-[(6-chloropyridin-3-yl)carbonyl]morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(6-chloropyridin-3-yl)carbonyl]morpholine(64614-49-9)
• EPA Substance Registry System: 4-[(6-chloropyridin-3-yl)carbonyl]morpholine(64614-49-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 64614-49-9(Hazardous Substances Data)

Usage

General Description

4-[(6-chloropyridin-3-yl)carbonyl]morpholine is a chemical compound with the molecular formula C11H11ClN2O2. It is a morpholine derivative containing a chloropyridin-3-yl carbonyl group. 4-[(6-chloropyridin-3-yl)carbonyl]morpholine is mainly used in the pharmaceutical industry as an intermediate for the synthesis of various drugs and pharmaceutical compounds. It is also utilized in research and development for its role as a building block in organic synthesis. The presence of the chloropyridin-3-yl carbonyl group makes this compound potentially useful in medicinal chemistry and drug discovery for the development of new pharmaceutical agents.

InChI:InChI=1/C10H11ClN2O2/c11-9-2-1-8(7-12-9)10(14)13-3-5-15-6-4-13/h1-2,7H,3-6H2

Upstream product

• 110-91-8 morpholine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 

Downstream Products

• 1178884-20-2 6-tert-butyl-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3,4-dihydro-2H-isoquinolin-1-one 
• 1198765-28-4 C₃₄H₃₄N₆O₅ 
• 1178884-09-7 6-(dimethylamino)-2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1161846-71-4 4-tert-butyl-N-{2-methyl-3-[8-({5-[(morpholin-4-yl)carbonyl]pyridin-2-yl}amino)imidazo[1,2-a]pyridin-6-yl]phenyl}benzamide 
• 1033836-14-4 6-(3-fluorophenyl)-N-{1-[5-(morpholin-4-ylcarbonyl)pyridin-2-yl]piperidin-4-yl}nicotinamid 
• 460747-00-6 2-iodo-4-[5-(4-morpholinylcarbonyl)-2-pyridinyl]phenol 
• 477740-54-8 [6-(4-hydroxy-phenyl)-pyridin-3-yl]-morpholin-4-yl-methanone 

Relevant articles and documents

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

A new class of potent non-imidazole H3 antagonists: 2-Aminoethylbenzofurans

2-Aminoethylbenzofurans constitute a new class of H3 antagonists that are more rotationally constrained than most previously reported H3 antagonists. They retain high potency at human and rat receptors, with efficient CNS penetration observed in 35. The SAR of the basic amine moiety was compared in three different series of analogues. The greatest potency was found in analogues bearing a 2-methylpyrrolidine, a 2,5-dimethylpyrrolidine, or a 2,6-dimethylpiperidine.